Clofarabine

( DrugBank: Clofarabine / KEGG DRUG: Clofarabine )


5 diseases
IDDisease name (Link within this page)Number of trials
19Lysosomal storage disease2
20Adrenoleukodystrophy1
60Aplastic anemia1
IDDisease name (Link within this page)Number of trials
96Crohn disease2
234Peroxisomal disease (except Adrenoleukodystrophy)1

19. Lysosomal storage disease


Clinical trials : 990Drugs : 584 - (DrugBank : 126) / Drug target genes : 62 - Drug target pathways : 192 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 68Drugs : 74 - (DrugBank : 32) / Drug target genes : 25 - Drug target pathways : 131 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

60. Aplastic anemia


Clinical trials : 305Drugs : 328 - (DrugBank : 91) / Drug target genes : 60 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,737Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

234. Peroxisomal disease (except Adrenoleukodystrophy)


Clinical trials : 115Drugs : 59 - (DrugBank : 20) / Drug target genes : 15 - Drug target pathways : 50 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries